- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07948070
A Phase I/II Open-label Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of Rejuvenated Tumor-Reactive T Cells (GKPTZ-01) in Subjects With Pancreatic Cancer
Clinical Application Study of Rejuvenated Tumor-Reactive T Cells in Pancreatic Cancer
A Phase I/II Open-label Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of Rejuvenated Tumor-Reactive T Cells (GKPTZ-01) in Subjects with Pancreatic Cancer
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Hao Jihui
- Telefonnummer: +86-02223340123
- E-post: haojihui@tjmuch.com
Studieorter
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Kina
- Rekrytering
- Tianjin Medical University Cancer Institute & Hospital
-
Kontakt:
- Hao Jihui, MD
- Telefonnummer: +86-02223340123
- E-post: haojihui@tjmuch.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Informed Consent Form (ICF) .
- Aged 18 to 70 years (inclusive) at the time of signing the ICF.
- Cytology or pathology confirmed Patients with pancreatic tumors.
Cohort 1:
- The subject has undergone radical total resection of the primary tumor with curative intent, as determined by the investigator.
- Adjuvant chemotherapy completed, as determined by the investigator.
Cohort 2:
- Disease progression after prior standard systemic antitumor therapy for the current disease stage;
- Inability to continue standard therapy due to clinically significant and intolerable toxicities, as determined by the investigator, during prior standard treatment;
- No standard treatment option is currently available, tolerable, and expected to provide clinical benefit for the participant, based on current clinical practice and the investigator's judgment;
- For locally recurrent disease, radical surgical resection is deemed unsuitable by the investigator.
Cohort 3:
-
Patients receiving standard chemotherapy regimens include, but are not limited to:
- the oFOLFIRINOX regimen;
- gemcitabine combined with nab-paclitaxel; or
- other standard first-line or second-line chemotherapy regimens as determined by the investigator according to local clinical practice guidelines.
-
Patients receiving targeted therapy must meet all the following criteria:
- Molecular testing confirms a clearly actionable biomarker abnormality (including, but not limited to, BRCA1/2 mutations, KRAS G12C mutation, HER2 alterations, NTRK fusions, or MSI-H/dMMR status);
- The investigator determines that no contraindications exist for the proposed targeted therapy.
-
ECOG score of 0 ~1 .
-
Expected survival time is more than 12 weeks.
-
Negative blood pregnancy test for females of childbearing potential is required.
Exclusion Criteria:
- Patients with central nervous system (CNS) metastasis, leptomeningeal disease, or metastatic spinal cord compression; or a history of CNS disorders, including but not limited to epilepsy, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, etc.
- History of bone marrow or organ transplantation;
- History of other primary malignancies;
- Hepatitis B surface antigen (HBsAg) positivity; With negative HBsAg but positive hepatitis B core antibody (HBcAb) ,and if peripheral blood hepatitis B virus (HBV) DNA positive; Hepatitis C virus (HCV) antibody positive and HCV RNA positive; Human immunodeficiency virus (HIV) antibody positive; Cytomegalovirus (CMV) DNA positive; Both Treponema pallidum-specific and non-specific antibody tests are positive.
- Patients with a known allergy to any component of the study drugs.
- History of active tuberculosis infection within 1 year prior to screening (subjects with a history of active tuberculosis infection more than 1 year ago are eligible if, in the investigator's judgment, there is no current evidence of active tuberculosis).
- Concurrent or previous history of interstitial lung disease or interstitial pneumonia; presence of chronic lung disease or other respiratory conditions that significantly impair lung function.
- Diagnosis of active autoimmune disease or a history of autoimmune disease that may recur (e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vasculitis, psoriasis, etc.), or at risk of such conditions.
- Clinically significant thyroid dysfunction as assessed by the investigator.
- Any uncontrolled active infection requiring parenteral (IV) antibiotic, antiviral, or antifungal treatment at the time of signing the ICF or within 4 weeks before the first infusion.
- Clinically significant cardiovascular diseases.
- Insufficient bone marrow reserve or insufficient organ function.
- Female subjects who are pregnant or breastfeeding.
- Administration of attenuated or inactivated vaccines within 28 days before signing the ICF, or planned administration of such vaccines during the screening period.
- The investigator considers that the subject's complications or other conditions may affect compliance with the protocol or that the subject is unsuitable for participation in this study.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Kohort 1
|
Combination with Adjuvant Chemotherapy |
|
Experimentell: Kohort 2
|
GKPTZ-01 |
|
Experimentell: Kohort 3
|
Combination with Chemotherapy or Targeted Therapy |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Recurrence-Free Survival
Tidsram: 2 years
|
6 months RFS(recurrence-free survival) rate(cohort 1) |
2 years
|
|
Objective response rate
Tidsram: 2 years
|
Proportion of subjects achieving complete response (CR) and partial response (PR)(cohort 2&3) |
2 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Disease Control Rate(DCR)
Tidsram: 2 years
|
Proportion of subjects achieving best response of CR, PR, or SD treated with GKPTZ-01 |
2 years
|
|
Duration of Response(DOR)
Tidsram: 2 years
|
Time from first documented evidence of confirmed CR or PR until the first documented evidence of disease progression or death, whichever occurs earlier |
2 years
|
|
Progression-free Survival(PFS)
Tidsram: 2 years
|
Time from GKPTZ-01 treatment to disease progression or death |
2 years
|
|
Overall survival(OS)
Tidsram: 2 years
|
Time from GKPTZ-01 treatment to death |
2 years
|
|
Adverse events
Tidsram: 2 years
|
The incidence and severity of AEs (Adverse Events) and SAEs (Serious Adverse Events). |
2 years
|
|
Patient Quality of Life
Tidsram: 2 years
|
EORTC(European Organisation for Research and Treatment of Cancer) QLG (Quality of Life Group)Core Questionnaire (EORTC QLQ-C30) |
2 years
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Pharmacokinetic
Tidsram: 2 years
|
Levels of T-cell Receptor copies |
2 years
|
|
Biomarker
Tidsram: 2 years
|
Concentration levels of serum cytokines, tumor markers |
2 years
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- GATEWAY
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .